This article was published on April 21, 2022
Modafinil (Provigil®)
Modafinil has an FDA indication “to improve wakefulness in adult patients excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD)”.
Related Pages
Modafinil (Provigil®): Basic Information
Do modafinil/ armodafinil need cardiovascular monitoring
Modafinil for ADHD?
Modafinil as an adjunct for major depressive disorder?
Armodafinil (Nuvigil®)
Armodafinil has an FDA indication “to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD)”.
Related Pages
Armodafinil (Nuvigil®): Basic Information
Do modafinil/ armodafinil need cardiovascular monitoring
Solriamfetol (Sunosi®)
A dopamine and norepinephrine reuptake inhibitor (DNRI) with an FDA indication “to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA)”.
Pitolisant (Wakix®)
A histamine-3 (H3) receptor antagonist/inverse agonist with an FDA indication “for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy“.
Related Pages
Clinical tips on excessive daytime sleepiness (hypersomnolence)
Medications for excessive daytime sleepiness (due to sleep apnea, narcolepsy, or shift work disorder)
Excessive daytime sleepiness after remission of major depression
Copyright © 2022, Simple and Practical Medical Education, LLC. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other laypersons or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.
Leave a Reply: